Anti-SHP2 antibody (ab131541)
Key features and details
- Rabbit polyclonal to SHP2
- Suitable for: WB, IHC-P, ICC/IF
- Reacts with: Mouse, Human
- Isotype: IgG
Overview
-
Product name
Anti-SHP2 antibody
See all SHP2 primary antibodies -
Description
Rabbit polyclonal to SHP2 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-P, ICC/IFmore details -
Species reactivity
Reacts with: Mouse, Human -
Immunogen
Synthetic peptide conjugated to KLH, derived from around amino acids 540-544 (
H-E-Y-T-N
) of Human SHP2 (NP_002825.3). -
Positive control
- HeLa cells; 3T3 cell extract; Human breast carcinoma tissue
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 0.88% Sodium chloride, 49% PBS, 50% Glycerol (glycerin, glycerine)
PBS without Mg2+ and Ca2+ -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab131541 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/500 - 1/1000. Predicted molecular weight: 68 kDa.
|
|
IHC-P |
1/50 - 1/100.
|
|
ICC/IF |
1/100 - 1/200.
|
Notes |
---|
WB
1/500 - 1/1000. Predicted molecular weight: 68 kDa. |
IHC-P
1/50 - 1/100. |
ICC/IF
1/100 - 1/200. |
Target
-
Function
Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus. -
Tissue specificity
Widely expressed, with highest levels in heart, brain, and skeletal muscle. -
Involvement in disease
Defects in PTPN11 are the cause of LEOPARD syndrome type 1 (LEOPARD1) [MIM:151100]. It is an autosomal dominant disorder allelic with Noonan syndrome. The acronym LEOPARD stands for lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and deafness.
Defects in PTPN11 are the cause of Noonan syndrome type 1 (NS1) [MIM:163950]. Noonan syndrome (NS) is a disorder characterized by dysmorphic facial features, short stature, hypertelorism, cardiac anomalies, deafness, motor delay, and a bleeding diathesis. Some patients with Noonan syndrome type 1 develop multiple giant cell lesions of the jaw or other bony or soft tissues, which are classified as pigmented villomoduolar synovitis (PVNS) when occurring in the jaw or joints. Note=Mutations in PTPN11 account for more than 50% of the cases. Rarely, NS is associated with juvenile myelomonocytic leukemia (JMML). NS1 inheritance is autosomal dominant.
Defects in PTPN11 are a cause of juvenile myelomonocytic leukemia (JMML) [MIM:607785]. JMML is a pediatric myelodysplastic syndrome that constitutes approximately 30% of childhood cases of myelodysplastic syndrome (MDS) and 2% of leukemia. It is characterized by leukocytosis with tissue infiltration and in vitro hypersensitivity of myeloid progenitors to granulocyte-macrophage colony stimulating factor.
Defects in PTPN11 are a cause of metachondromatosis (MC) [MIM:156250]. It is a skeletal disorder with radiologic fetarures of both multiple exostoses and Ollier disease, characterized by the presence of multiple enchondromas and osteochondroma-like lesions. -
Sequence similarities
Belongs to the protein-tyrosine phosphatase family. Non-receptor class 2 subfamily.
Contains 2 SH2 domains.
Contains 1 tyrosine-protein phosphatase domain. -
Domain
The SH2 domains repress phosphatase activity. Binding of these domains to phosphotyrosine-containing proteins relieves this auto-inhibition, possibly by inducing a conformational change in the enzyme. -
Post-translational
modificationsPhosphorylated on Tyr-546 and Tyr-584 upon receptor protein tyrosine kinase activation; which creates a binding site for GRB2 and other SH2-containing proteins. -
Cellular localization
Cytoplasm. - Information by UniProt
-
Database links
- Entrez Gene: 5781 Human
- Entrez Gene: 19247 Mouse
- Omim: 176876 Human
- SwissProt: Q06124 Human
- SwissProt: P35235 Mouse
- Unigene: 506852 Human
- Unigene: 474046 Mouse
- Unigene: 8681 Mouse
-
Alternative names
- BPTP3 antibody
- CFC antibody
- JMML antibody
see all
Images
-
Immunohistochemical analysis of paraffin-embedded Human breast carcinoma tissue labelling SHP2 with ab131541 at 1/50 dilution. Right panel was preincubated with blocking peptide.
-
Anti-SHP2 antibody (ab131541) at 1/500 dilution + 3T3 cell extract
Predicted band size: 68 kDa -
Immunofluorescence analysis of methanol-fixed HeLa cells labelling SHP2 with ab131541 at 1/100 dilution.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (9)
ab131541 has been referenced in 9 publications.
- Zhang Y et al. Phosphatase Shp2 regulates biogenesis of small extracellular vesicles by dephosphorylating Syntenin. J Extracell Vesicles 10:e12078 (2021). PubMed: 33732417
- Chen X et al. Ropivacaine inhibits cervical cancer cell growth via suppression of the miR-96/MEG2/pSTAT3 axis. Oncol Rep 43:1659-1668 (2020). PubMed: 32323811
- Xiao J et al. Combined administration of SHP2 inhibitor SHP099 and the a7nAChR agonist PNU282987 protect mice against DSS-induced colitis. Mol Med Rep 22:2235-2244 (2020). PubMed: 32705242
- Cheung KCP et al. Preservation of microvascular barrier function requires CD31 receptor-induced metabolic reprogramming. Nat Commun 11:3595 (2020). PubMed: 32681081
- Yue X et al. SHP2 knockdown ameliorates liver insulin resistance by activating IRS-2 phosphorylation through the AKT and ERK1/2 signaling pathways. FEBS Open Bio 10:2578-2587 (2020). PubMed: 33012117
- Yue J et al. Upregulated SHP-2 expression in the epileptogenic zone of temporal lobe epilepsy and various effects of SHP099 treatment on a pilocarpine model. Brain Pathol 30:373-385 (2020). PubMed: 31398269
- Cao J et al. Clinicopathological and prognostic significance of SHP2 and Hook1 expression in patients with thyroid carcinoma. Hum Pathol N/A:N/A (2018). PubMed: 29953894
- Teng JF et al. Lentivirus-Mediated Silencing of Src Homology 2 Domain-Containing Protein Tyrosine Phosphatase 2 Inhibits Release of Inflammatory Cytokines and Apoptosis in Renal Tubular Epithelial Cells Via Inhibition of the TLR4/NF-kB Pathway in Renal Ischemia-Reperfusion Injury. Kidney Blood Press Res 43:1084-1103 (2018). PubMed: 29991025
- Kamiya N et al. SHP2-Deficiency in Chondrocytes Deforms Orofacial Cartilage and Ciliogenesis in Mice. J Bone Miner Res 30:2028-32 (2015). PubMed: 25919282